B. Riley Comments on InfuSystem’s Q2 Earnings (NYSE:INFU)

InfuSystem Holdings, Inc. (NYSE:INFU) – Stock analysts at B. Riley reduced their Q2 2025 EPS estimates for InfuSystem in a research note issued to investors on Tuesday, March 4th. B. Riley analyst K. Bauser now anticipates that the company will post earnings of $0.05 per share for the quarter, down from their prior estimate of $0.06. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s FY2025 earnings at $0.23 EPS.

Separately, StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th.

InfuSystem Trading Down 3.7 %

Shares of INFU stock opened at $6.23 on Thursday. InfuSystem has a 1 year low of $5.74 and a 1 year high of $9.97. The firm’s fifty day simple moving average is $8.00 and its 200 day simple moving average is $7.61. The firm has a market capitalization of $132.47 million, a P/E ratio of 103.85 and a beta of 1.75. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Institutional Investors Weigh In On InfuSystem

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after buying an additional 1,626 shares during the period. Wells Fargo & Company MN increased its holdings in InfuSystem by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock valued at $78,000 after buying an additional 3,165 shares during the period. Legato Capital Management LLC bought a new stake in InfuSystem in the 4th quarter valued at $85,000. Summit Global Investments bought a new stake in InfuSystem in the 4th quarter valued at $86,000. Finally, Sei Investments Co. bought a new stake in InfuSystem in the 4th quarter valued at $90,000. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.